B+
Bull case
0%
Probability
Target price
$208.00
+14.7% vs current
CRL
Charles River Laboratories InternationalANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
1%
Probability
Target price
$193.00
+6.4% vs current
B-
Bear case
0%
Probability
Target price
$165.00
-9.0% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+47.1
Score
AI commentary
Primary-source evidence is strong because the May 7, 2026 earnings release, 8-K, and 10-Q are available and coherent. Trusted coverage on May 7 framed the print as an earnings beat helped by steadier drug-development demand, but the release itself also showed organic declines and lower non-GAAP margin. Immediate analyst revision evidence was not available in the packet at this T+1 follow-up, so the correct read is cautious monitoring rather than a clean rerating call; the May 7 close anchor of $181.68 does not by itself prove sustained post-print momentum.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-07catalystQ1 beat versus consensus, guidance reaffirmed, and DSA bookings stayed supportiveMedium impact
Charles River reported Q1 2026 revenue of $995.8M, non-GAAP EPS of $2.06, reaffirmed 2026 organic revenue and non-GAAP EPS guidance, and said DSA demand was tracking to expectations with solid first-quarter bookings; Reuters reported adjusted EPS topped the $1.94 LSEG consensus. Offsetting that, organic revenue still declined 1.5% and non-GAAP operating margin fell to 16.3%. [#8-K-2026-05-07]
2026-08-06eventPortfolio reshaping through divestitures can simplify mix, but Q2 cleanup risk remainsMedium impact
The company completed the CDMO and Cell Solutions divestiture on May 6, 2026, and guidance assumes the planned sale of certain European Discovery Services sites closes in May 2026. The 10-Q also says Charles River may have to fund up to $45.0M of future EBITDA losses and capex for the divested businesses and expects the final loss on sale analysis to be recognized in Q2 2026, keeping execution risk live. [#10-Q-2026-05-07]
2027-05-08catalystRecent acquisitions could strengthen supply and manufacturing-quality offerings over timeHigh impact
The 10-Q says Charles River acquired PathoQuest on April 17, 2026 for about $60.0M and completed the K.F. Cambodia asset acquisition on January 14, 2026 for a preliminary $507.3M purchase price. Those moves can improve manufacturing quality-control capabilities and internal NHP supply, but they also raise integration and leverage sensitivity before benefits are fully proven. [#10-Q-2026-05-07]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology